Zifang Deng1, Fenfei Leng1. 1. Biomolecular Sciences Institute and Department of Chemistry and Biochemistry, Florida International University, Miami, Florida 33199, United States.
Abstract
DNA topoisomerases, essential enzymes to all living organisms, are important targets of certain antibiotics and anticancer drugs. Although efforts have been taken to identify new inhibitors targeting DNA topoisomerases, limited high throughput screening (HTS) studies have been conducted since a widely accessible HTS assay is not available. We report here the establishment of a fluorescence-based, low-cost HTS assay to identify topoisomerase inhibitors. This HTS assay is based on a unique property of T5 exonuclease that can completely digest supercoiled plasmid pAB1 containing an "AT" hairpin structure and spare relaxed pAB1 and has been validated by screening a small library that contains 50 compounds for various topoisomerases. This T5 exonuclease-based HTS assay can also be used to identify DNA intercalators, the major false positives for identifying topoisomerase inhibitors using this HTS assay. Additionally, we found a new compound that potently inhibits human and bacterial DNA topoisomerase I.
DNA topoisomerases, essential enzymes to all living organisms, are important targets of certain antibiotics and anticancer drugs. Although efforts have been taken to identify new inhibitors targeting DNA topoisomerases, limited high throughput screening (HTS) studies have been conducted since a widely accessible HTS assay is not available. We report here the establishment of a fluorescence-based, low-cost HTS assay to identify topoisomerase inhibitors. This HTS assay is based on a unique property of T5 exonuclease that can completely digest supercoiled plasmid pAB1 containing an "AT" hairpin structure and spare relaxed pAB1 and has been validated by screening a small library that contains 50 compounds for various topoisomerases. This T5 exonuclease-based HTS assay can also be used to identify DNA intercalators, the major false positives for identifying topoisomerase inhibitors using this HTS assay. Additionally, we found a new compound that potently inhibits human and bacterial DNA topoisomerase I.
DNA supercoiling or
topology is a property deeply rooted in the
DNA double helix.[1] Typically, naturally
occurring DNA is (−) supercoiled (sc).[1−3] Free energy
constrained in the (−) supercoiling of DNA molecules greatly
promotes a number of essential DNA processes, such as DNA replication,
DNA recombination, and transcription.[1,3] For instance,
all stages of DNA replication have topological issues.[1,3,4] Usually, (−) supercoiling
favors the formation of functional initiation complexes.[5−9] In some cases, DNA replication initiation depends on (−)
supercoiling.[7,10] As the replication forks progressively
move along the DNA double helix, (+) supercoils build up in front
of the moving replication forks.[11] Without
removing the (+) supercoils by a DNA topoisomerase, DNA replication
forks would be arrested.[12] For DNA replication
termination, the newly replicated daughter DNA molecules would form
catenated DNA and not separate into individual daughter DNA molecules
without the assistance of a DNA topoisomerase.[13−15] These examples
demonstrate the essentiality of DNA topology and topoisomerases. Because
of their importance to living organisms, DNA topoisomerases are the
targets of certain clinically important antibiotics and anticancer
drugs.[16−18] Bacterial DNA gyrase and topoisomerase IV are the
targets of quinolones, one of the most important and prescribed antibiotics.[19−22] Human topoisomerases I and II are the targets of anticancer drugs,
such as camptothecin/topotecan,[16,23] doxorubicin,[16] and etoposide.[24]Agarose gel electrophoresis is the most commonly used biochemical
assay to study DNA supercoiling and topoisomerases.[25−27] This assay
has several advantages: it is cheap, quick, convenient, and widely
accessible.[1] Single topoisomer resolution
can be achieved.[25,26] The (−) and (+) supercoils
can also be differentiated.[1,28] Nevertheless, agarose
gel electrophoresis is a time-consuming and labor-intensive assay
and cannot be used as a high throughput screening (HTS) assay to identify
topoisomerase inhibitors.[27] Utilizing certain
properties of sc DNA molecules, different screening assays have been
established to identify inhibitors targeting DNA topoisomerases.[29−33] However, these methods have their own limits. For instance, a type
of unique fluorescently labeled DNA molecules has been synthesized
to study DNA topoisomerases by fluorescence resonance energy transfer
or supercoiling-dependent fluorescence quenching (SDFQ).[33,34] This assay stems from a property of alternating (AT)n sequences in the closed circular plasmids that undergo rapid cruciform
formation–deformation depending on the supercoiling status
of the plasmids.[35,36] The distance between a pair of
fluorophore–quencher inserted in the (AT)n sequence
is dramatically changed when the plasmids adopt an sc or relaxed (rx)
form.[33] These DNA molecules are excellent
tools to examine relaxation/supercoiling kinetics of various DNA topoisomerases[34] and can be configured into HTS assays to identify
topoisomerase inhibitors.[33] Indeed, we
are using the SDFQ-based HTS assays to identify inhibitors targeting
bacterial DNA gyrase and bacterial DNA topoisomerase I. Nevertheless,
the synthesis of this type of fluorescently labeled DNA molecules
is expensive. Certain potential topoisomerase inhibitors have fluorescence
that greatly interferes with the final detection signal. Additionally,
DNA intercalators that transiently unwind and relax the (−)
sc DNA also interfere with the identification of topoisomerase inhibitors.
A different, less expensive HTS assay is needed and may be used as
an orthogonal assay for the HTS efforts.Here, we report the
establishment of new types of HTS assays to
discover/identify topoisomerase inhibitors based on a unique property
of T5 exonuclease. Under certain experimental conditions, T5 exonuclease
can completely degrade the sc plasmid pAB1 that carries a hairpin
structure. In contrast, it does not digest the rx pAB1. This unique
property can be used to differentiate sc and rx pAB1 and then identify
topoisomerase inhibitors. A 50-compound library that contains several
known DNA gyrase inhibitors are used to validate these HTS assays
for various DNA topoisomerases. This T5 exonuclease-based assay can
also be used to identify DNA intercalators and remove them as false
positives from the potential DNA topoisomerase inhibitors. Furthermore,
we found a new compound that potently inhibits Escherichia
coli and human DNA topoisomerase I.
Results and Discussion
T5 Exonuclease
Completely Degraded (−) sc Plasmid pAB1
That Carries an AT Hairpin Structure
Previous studies showed
that T5 exonuclease can completely digest single-stranded DNA, linear
double-stranded DNA, and nicked plasmid DNA molecules.[38−40] It does not degrade (−) sc or rx plasmid DNA molecules, such
as (−) sc or rx pUC18.[38−40] We confirmed these results showing
that the purified T5 exonuclease in our laboratory also completely
removed/digested nicked (nk) pUC18 (compare lane 4 to lane 6 of Figure a) and did not degrade
either (−) sc or rx pUC18 (lanes 5 and 6 of Figure a). Interestingly, we found
that T5 exonuclease completely degraded (−) sc plasmid pAB1
that carries an AT hairpin structure (lane 3 of Figure a and Figure b) and, in contrast, did not digest rx pAB1 (lane 2
of Figure a). A likely
scenario is that the endonucleolytic activity of T5 exonuclease nicked
the AT hairpin structure of (−) sc pAB1 followed by the degradation
of the nicked plasmid by the 5′-3′ exonucleolytic activity
of T5 exonuclease.[41,42] Since the 42 bp AT sequence of
rx pAB1 adopts the double-stranded form, T5 exonuclease could not
degrade rx pAB1. This hypothetical mechanism is supported from the
observation that high concentrations of ATP, GTP, CTP, and UTP inhibited
the degradation of (−) sc pAB1 by T5 exonuclease (Figure a). Possibly, high
concentrations of these nucleotides inhibited the endonucleolytic
activities of T5 exonuclease and therefore prevented the enzyme to
nick and degrade the (−) sc pAB1.
Figure 1
T5 exonuclease (T5E)
can completely digest (−) sc plasmid
pAB1 that contains a hairpin structure. (a) T5E completely digested
(−) sc pAB1 (lanes 1–3) and cannot digest (−)
sc plasmid pUC18 (lanes 4–6; the parent plasmid). (b) Hairpin
structure is formed for the 42 nt AT sequence when pAB1 becomes (−)
supercoiled. Symbols: sc, supercoiled and rx, relaxed.
Figure 2
High concentrations of NTPs and dNTPs inhibit the T5E activities.
(a) sc pAB1 was used. C represents the (−) sc pAB1. (b) Fluorescently
labeled oligomer HP1 was used to test the FEN activities of T5E. The
5′ and 3′-end of HP1 are labeled with fluorescein (F)
and TAMRA (T), respectively. 3′-T and 5′-F represent
the TAMRA- and fluorescein-labeled products by T5E, respectively.
High concentrations of (c) NTPs and (d) dNTPs inhibit the T5E activities
using HP1 as the substrate. DNA samples were loaded onto 20% PAGE
gels in 1× TAE. Symbol C represents the HP1 DNA control sample.
T5 exonuclease (T5E)
can completely digest (−) sc plasmid
pAB1 that contains a hairpin structure. (a) T5E completely digested
(−) sc pAB1 (lanes 1–3) and cannot digest (−)
sc plasmid pUC18 (lanes 4–6; the parent plasmid). (b) Hairpin
structure is formed for the 42 nt AT sequence when pAB1 becomes (−)
supercoiled. Symbols: sc, supercoiled and rx, relaxed.High concentrations of NTPs and dNTPs inhibit the T5E activities.
(a) sc pAB1 was used. C represents the (−) sc pAB1. (b) Fluorescently
labeled oligomer HP1 was used to test the FEN activities of T5E. The
5′ and 3′-end of HP1 are labeled with fluorescein (F)
and TAMRA (T), respectively. 3′-T and 5′-F represent
the TAMRA- and fluorescein-labeled products by T5E, respectively.
High concentrations of (c) NTPs and (d) dNTPs inhibit the T5E activities
using HP1 as the substrate. DNA samples were loaded onto 20% PAGE
gels in 1× TAE. Symbol C represents the HP1 DNA control sample.The endonucleolytic activity of T5 exonuclease,
i.e., the flap
endonuclease (FEN) of T5 exonuclease, has been extensively studied
using oligomers of the DNA flap structures, such as HP1.[43−45] Specifically, T5 exonuclease cleaves the 29 nt. HP1 into two fragments,
an 8 nt. fragment and a 21 nt. hairpin.[43] In this study, we utilized a double fluorescently labeled HP1 with
fluorescein (F) and TAMRA (T) on the 5′- and 3′-end
(Figure b), respectively,
to examine whether high concentrations of NTPs or dNTPs inhibit the
FEN activities. Indeed, high concentrations of NTPs or dNTPs significantly
inhibited the FEN activities of T5 exonuclease (Figure c,d). These results are consistent with previously
published results that ATP inhibited the FEN activities of other nucleases.[46,47]
A T5 Exonuclease-Based HTS Assay for E. coli DNA Gyrase
Since T5 exonuclease completely degrades (−)
sc plasmid pAB1 and does not digest rx pAB1, this unique property
of T5 exonuclease can be used to study DNA topology and topoisomerases.
For instance, a T5 exonuclease-based assay may be established to identify
DNA topoisomerase inhibitors. Figure a shows an experimental strategy of such an assay to
screen/identify inhibitors targeting bacterial DNA gyrase. This assay
can be easily configured into a high throughput screening (HTS) format.
In the absence of gyrase inhibitors, DNA gyrase converts the rx plasmid
DNA templates into the (−) sc form. This conversion results
in the formation of a hairpin structure in the plasmid. As a result,
the (−) sc pAB1 was completely degraded by T5 exonuclease (lane
5 of Figure b). In
contrast, gyrase inhibitor novobiocin completely inhibited the E. coligyrase activities and prevented the conversion
of the rx plasmid pAB1 into the (−) sc form. T5 exonuclease
could not digest rx pAB1 (lane 6 of Figure b). A DNA staining dye, such as ethidium
homodimer 1 (EthD1), can differentiate the products from these two
T5 exonuclease-based reactions (Figure c). In the presence of a gyrase inhibitor, the fluorescence
intensity of EthD1 is significantly higher than that of the DNA sample
in the absence of a gyrase inhibitor (Figure c).
Figure 3
(a) T5 exonuclease (T5E)-based experimental
strategy to identify
inhibitors targeting bacterial DNA gyrase (Gyr). (b) Agarose gel results
show the feasibility of the T5E-based assay. T5E completely digested
the (−) sc pAB1 converted from rx pAB1 by E.
coli DNA gyrase (lane 5). T5E did not degrade the
rx pAB1 sample in the presence of E. coli DNA gyrase and novobiocin (lane 6). (c) DNA staining dye ethidium
homodimer 1 (EthD1) was used to differentiate the DNA samples in (b).
The fluorescence intensity was measured using a plate reader with
λem = 617 nm and λex = 528 nm. Lane
# are the same as (b). The symbol of “bk” represents
the background fluorescence of an empty well.
(a) T5 exonuclease (T5E)-based experimental
strategy to identify
inhibitors targeting bacterial DNA gyrase (Gyr). (b) Agarose gel results
show the feasibility of the T5E-based assay. T5E completely digested
the (−) sc pAB1 converted from rx pAB1 by E.
coli DNA gyrase (lane 5). T5E did not degrade the
rx pAB1 sample in the presence of E. coliDNA gyrase and novobiocin (lane 6). (c) DNA staining dye ethidium
homodimer 1 (EthD1) was used to differentiate the DNA samples in (b).
The fluorescence intensity was measured using a plate reader with
λem = 617 nm and λex = 528 nm. Lane
# are the same as (b). The symbol of “bk” represents
the background fluorescence of an empty well.A series of experiments were performed to determine the optimal
conditions for the T5 exonuclease-based HTS assay for E. coliDNA gyrase (Figure S1a–e). These experiments show that 10 μM (bp) pAB1 (Figure S1a), 200 nM T5 exonuclease (Figure S1b), and 20 nM E. coliDNA gyrase (Figure S1c) are optimal and
were chosen for the HTS assay. The assay tolerated up to 2% DMSO without
any significant change in signal. We also found that 2 h of incubation
with T5 exonuclease is needed for the assay (Figure S1d,e). Additionally, several different DNA staining dyes,
i.e., Hoechst 33258, SYBR green, SYBR gold, ethidium bromide, and
EthD1, with different fluorescence excitation and emission wavelengths
were examined (Figure S2). All can be used
in the assay depending on the fluorescence interference that the potential
gyrase inhibitors have. We found that most fluorescence interference
is between 400 and 500 nm. Hoechst 33258 with the maximum fluorescence
emission at 461 nm should not be used although it gives the highest
signal to background ratio (S/B)
(Figure S2a). We chose the use of EthD1
for the HTS assays because this DNA-binding dye tightly binds to DNA
and has good fluorescence signals upon DNA binding. If the budget
is a concern, ethidium bromide may be used (Figure S2d). After we optimized the conditions for the T5 exonuclease-based
assay for E. coliDNA gyrase, we performed
titration experiments in which different concentrations of novobiocin
and ciprofloxacin were added into the assays. Figure S3 shows our results. Ciprofloxacin and novobiocin
potently inhibited the activities of DNA gyrase with estimated IC50
values of 3.2 and 0.48 μM, respectively. These values are consistent
with our previously published results using SDFQ- and agarose gel-based
assays.[33]Next, we assembled a 50-compound
library that contains eight known
bacterial DNA gyrase inhibitors (Table S1) in order to establish and validate the T5 exonuclease-based HTS
assay for E. coliDNA gyrase. Figure and Table S2 show the results of this pilot screen
using chemical compounds at a final concentration of 20 μM in
triplicate with the following statistics: Z′,
0.64; S/B (the mean signal to mean
background ratio), 3.0; and nine hits. These nine hits are novobiocin,
five fluoroquinolones, suramin, echinomycin, and ethacridine. Novobiocin
and five fluoroquinolones are potent gyrase inhibitors and are expected
to completely inhibit E. coliDNA gyrase
activities at 20 μM. Suramin is a known DNA topoisomerase II
inhibitor.[48] It is not surprising that
20 μM suramin partially inhibits E. coliDNA gyrase activities. Echinomycin and ethacridine are two known
DNA intercalators and should be able to significantly unwind the plasmid
pAB1 at 20 μM.[49] In this case, plasmid
pAB1 was fully relaxed or (+) supercoiled. The 42 nt AT DNA sequence
adopted the double-stranded form and did not form a hairpin structure.
As a result, T5 exonuclease did not degrade the pAB1 DNA samples.
They are false positives. Another two gyrase inhibitors nalidixic
acid and oxolinic acid have IC50 values much greater than 20 μM[50] and was not expected to inhibit E. coliDNA gyrase activities under the experimental
conditions used here. Therefore, the T5 exonuclease-based assay could
not identify these two gyrase inhibitors. Although fluoroquinolones
are known to cause double-stranded DNA breaks through stabilizing
DNA-gyrase-drug complexes, we were still able to identify them as
potent gyrase inhibitors using this HTS assay. A possible mechanism
is that DNA gyrase covalently links to the plasmid DNA substrate when
fluoroquinolones stabilize the DNA-gyrase-fluoroquinolone complexes,
which prevents the access of T5 exonuclease to the DNA breaks. As
a result, DNA gyrase was inhibited and the DNA substrate (rx pAB1)
was not digested.
Figure 4
HTS pilot screen of the 50-compound library for E. coli DNA gyrase inhibitors in triplicate. A final
compound concentration of 20 μM was used. DMSO (1%) (red triangles)
and novobiocin (3 μM) (green squares) are used as negative and
positive controls, respectively. An inhibition of ≥50% against
bacterial DNA gyrase is used as the cutoff value for gyrase inhibitors.
HTS pilot screen of the 50-compound library for E. coliDNA gyrase inhibitors in triplicate. A final
compound concentration of 20 μM was used. DMSO (1%) (red triangles)
and novobiocin (3 μM) (green squares) are used as negative and
positive controls, respectively. An inhibition of ≥50% against
bacterial DNA gyrase is used as the cutoff value for gyrase inhibitors.
A T5 Exonuclease-Based HTS Assay to Identify
Potential DNA Intercalators
and T5 Exonuclease Inhibitors
As stated above, DNA intercalators
can unwind and transiently relax the (−) sc plasmid pAB1. High
concentrations of DNA intercalators may even convert (−) sc
plasmids into (+) sc plasmids.[1] Combining
with the unique property of T5 exonuclease that completely degrades
(−) sc plasmid pAB1 and does not digest rx pAB1, a T5 exonuclease-based
assay may be used to identify potential DNA intercalators, the major
false positives for the HTS assays. Figure a shows the experimental strategy for this
purpose. DNA intercalators can convert (−) sc pAB1 into the
rx form. As a result, the 42 nt AT DNA sequence adopts the double-stranded
form and T5 exonuclease cannot degrade this transiently rx pAB1. In
contrast, T5 exonuclease is able to completely digest (−) sc
pAB1. As discussed above, a DNA-binding dye should differentiate these
two forms of DNA samples. Please note that the positive hits also
include potential T5 exonuclease inhibitors since the inhibition of
T5 exonuclease also prevents the degradation of (−) sc pAB1
and results in the high fluorescence output.
Figure 5
(a) T5E-based experimental
strategy to identify potential DNA intercalators.
Please note that the positive hits also include compounds that inhibit
T5 exonuclease activities. (b) HTS pilot screen of the 50-compound
library for DNA intercalators. Data represent the mean value ±
standard deviation (SD) of three independent experiments. DMSO (1
%) (red triangles) was used as negative controls. DNA samples in the
presence of 20 μM echinomycin were used as the positive controls
(green squares). A final compound concentration of 20 μM was
used.
(a) T5E-based experimental
strategy to identify potential DNA intercalators.
Please note that the positive hits also include compounds that inhibit
T5 exonuclease activities. (b) HTS pilot screen of the 50-compound
library for DNA intercalators. Data represent the mean value ±
standard deviation (SD) of three independent experiments. DMSO (1
%) (red triangles) was used as negative controls. DNA samples in the
presence of 20 μM echinomycin were used as the positive controls
(green squares). A final compound concentration of 20 μM was
used.We screened the 50-compound library
using this assay at a final
compound concentration of 20 μM in triplicate and got the following
statistics: Z′, 0.63; S/B, 5.5; and three hits (suramin, echinomycin, and ethacridine)
(Figure b). Echinomycin
and ethacridine are potent DNA intercalators with a Kd (dissociation constant) at the sub-micromolar range
and form strong DNA intercalation complexes.[49,51] It is expected that both echinomycin and ethacridine fully relax
(−) sc plasmid pAB1 at 20 μM. As a result, T5 exonuclease
could not degrade the rx pAB1 and yielded a high fluorescence output
(Figure b). Suramin,
a century-old antiparasitic drug that carries 6 negative charges under
physiological conditions, inhibits many enzymes including those involved
in nucleic acid metabolisms.[52] Possibly,
suramin also inhibits T5 exonuclease. Indeed, our results showed that
suramin inhibits the endonucleolytic or FEN activity of T5 exonuclease
with an IC50 of 22.6 μM (Figure S4a–c).
T5 Exonuclease-Based HTS Assays for DNA Topoisomerases That
Relax (−) sc Plasmid DNA Molecules
We also established
several T5 exonuclease-based HTS assays to screen and identify inhibitors
for DNA topoisomerases, e.g., bacterial DNA topoisomerase I, human
DNA topoisomerase I, and human DNA topoisomerase IIα that relax
(−) sc DNA templates. Figure a shows an experimental strategy to screen/identify
inhibitors targeting E. coli DNA topoisomerase
I (EcTopI). In the absence of an inhibitor, EcTopI relaxes the sc
plasmid pAB1 into the rx form. This relaxation results in the conversion
of the hairpin structure of pAB1 into the double-stranded form. In
this case, T5 exonuclease cannot digest the rx pAB1 (lane 2 of Figure a). In contrast,
an EcTopI inhibitor prevents the conversion of the sc plasmid pAB1
into the rx form. T5 exonuclease completely degrades sc pAB1. A DNA
staining dye, such as ethidium homodimer 1 (EthD1), can be used to
differentiate these two DNA samples.
Figure 6
(a) T5E-based experimental strategy to
identify inhibitors targeting E. coli DNA topoisomerase I (EcTopI). Please note
that the same strategy can be used to identify inhibitors targeting
other DNA topoisomerases, such as HuTopI and HuTopIIα, that
relax the (−) sc DNA. (b) HTS pilot screen of the 50-compound
library for EcTopI inhibitors. Data represent the mean value ±
standard deviation (SD) of three independent experiments. DMSO (1
%) (red triangles) was used as negative controls. Due to the lack
of a proper bacterial topoisomerase I inhibitor as a positive control,
DNA samples in the absence of the EcTopI were used as our positive
controls (green squares). A final compound concentration of 20 μM
was used.
(a) T5E-based experimental strategy to
identify inhibitors targeting E. coli DNA topoisomerase I (EcTopI). Please note
that the same strategy can be used to identify inhibitors targeting
other DNA topoisomerases, such as HuTopI and HuTopIIα, that
relax the (−) sc DNA. (b) HTS pilot screen of the 50-compound
library for EcTopI inhibitors. Data represent the mean value ±
standard deviation (SD) of three independent experiments. DMSO (1
%) (red triangles) was used as negative controls. Due to the lack
of a proper bacterial topoisomerase I inhibitor as a positive control,
DNA samples in the absence of the EcTopI were used as our positive
controls (green squares). A final compound concentration of 20 μM
was used.We screened the 50-compound library
using this assay and found
three hits. The following are the screening statistics using a compound
concentration of 20 μM: a Z′ value of
0.68 and S/B ratio of 3.3. These
three hits are suramin, NSC668394, and NSC97419. As mentioned above,
the highly negatively charged suramin inhibits many enzymes.[52] It is not surprising that suramin also inhibits
EcTopI. Indeed, our agarose gel-based topoisomerase assays confirmed
this result (Figure S4d). We could not
confirm that NSC97419, a polyphenol, inhibits EcTopI activities using
the agarose gel-based topoisomerase assay. The most intriguing compound
is the quinolinedioneNSC668394, an ezrin inhibitor[53,54] that almost completely inhibited the EcTopI activities in the HTS
assay (Figure b and Figure S5). We, therefore, performed an agarose
gel-based EcTopI inhibition assay and found that NSC668394 strongly
inhibited the EcTopI activities with an IC50 of 8.0 ± 0.2 μM
(Figure a). Since
NSC668394 carries a benzoquinone moiety that should be reactive toward
thiol groups,[55] a possible mechanism of
this inhibition is through the formation of a covalent bond with cysteine
residues of EcTopI since certain cysteine residues are critical for
the EcTopI activities.[56] If this hypothesis
is correct, DTT should be able to abolish the EcTopI inhibition of
NSC668394. Figure b shows our results. Indeed, NSC668394 did not inhibit EcTopI activities
in the presence of 1 mM DTT (compare lane 1 with lanes 2 and 3 of Figure b). The visible spectra
of NSC668394 in the presence and absence of DTT are dramatically different,
indicating that NSC668394 formed covalent bonds with thiols of DTT
(Figure c).
Figure 7
Compound NSC668394
potently inhibits EcTopI and human DNA topoisomerase
I (HuTopI) activities. (a) Inhibition of EcTopI by NSC668394 in the
absence of DTT. The DNA relaxation assays were performed as described
in the Experimental Section in 1× CutSmart
buffer using (−) sc pAB1. Lanes 2–8 contain 0, 2.5,
5, 7.5, 10, 20, and 50 μM NSC668394, respectively. Lane 1 is
the (−) sc pAB1. (b) DTT (1 mM) abolishes the EcTopI inhibition
of NSC668394. The DNA relaxation assays were performed as described
in the Experimental Section in 1× EcTopI
buffer (lanes 1 and 2; 1× EcTopI buffer: 40 mM Tris-HCl, pH 8,
5 mM MgCl2, 25 mM KCl, 1 mM DTT, 0.1 mg/mL BSA, and 3% glycerol) or
1× CutSmart buffer (lanes 3–5) using (−) sc pAB1.
1 mM DTT was added to the reaction mixtures of lanes 3 and 5. (c)
UV/VIS spectra of NSC668394 (100 μM) in the absence (black line)
or presence (red line) of 1 mM DTT in 10 mM Tris-HCl (pH 8.0). (d)
Inhibition of HuTopI by NSC668394 in the absence of DTT. The DNA relaxation
assays were performed as described in the Experimental
Section in 1× HuTopI buffer (10 mM Tris-HCl, pH 7.9, 150
mM NaCl, 0.1% BSA, 0.1 mM spermidine, and 5% glycerol) using (−)
sc pAB1.
Compound NSC668394
potently inhibits EcTopI and human DNA topoisomerase
I (HuTopI) activities. (a) Inhibition of EcTopI by NSC668394 in the
absence of DTT. The DNA relaxation assays were performed as described
in the Experimental Section in 1× CutSmart
buffer using (−) sc pAB1. Lanes 2–8 contain 0, 2.5,
5, 7.5, 10, 20, and 50 μM NSC668394, respectively. Lane 1 is
the (−) sc pAB1. (b) DTT (1 mM) abolishes the EcTopI inhibition
of NSC668394. The DNA relaxation assays were performed as described
in the Experimental Section in 1× EcTopI
buffer (lanes 1 and 2; 1× EcTopI buffer: 40 mM Tris-HCl, pH 8,
5 mM MgCl2, 25 mM KCl, 1 mM DTT, 0.1 mg/mL BSA, and 3% glycerol) or
1× CutSmart buffer (lanes 3–5) using (−) sc pAB1.
1 mM DTT was added to the reaction mixtures of lanes 3 and 5. (c)
UV/VIS spectra of NSC668394 (100 μM) in the absence (black line)
or presence (red line) of 1 mM DTT in 10 mM Tris-HCl (pH 8.0). (d)
Inhibition of HuTopI by NSC668394 in the absence of DTT. The DNA relaxation
assays were performed as described in the Experimental
Section in 1× HuTopI buffer (10 mM Tris-HCl, pH 7.9, 150
mM NaCl, 0.1% BSA, 0.1 mM spermidine, and 5% glycerol) using (−)
sc pAB1.Human DNA topoisomerase I (HuTopI)
also contains eight cysteine
residues that are critical for its activities.[57] Previous results showed that alkylation of the HuTopI cysteine
residues by thiol modification compounds, such as N-ethylmaleimide, resulted in the loss of HuTopI activities in vitro.(57,58) We wondered whether NSC668394
could also inhibit the HuTopI activities. Our results in Figure d show that NSC668394
strongly inhibited HuTopI with an IC50 of 5 ± 1.4 μM. Again,
DTT abolished the inhibition of NSC668394 against HuTopI (Figure S4e), suggesting that the inhibition is
through the formation of covalent bonds with the thiol groups of cysteine
residues in the enzyme.In this study, we also developed a T5
exonuclease-based HTS assay
(Figure S6a) to identify inhibitors targeting variola DNA topoisomerase I (vTopI), a type IB DNA topoisomerase,
and screened the 50-compound library with the following statistics: Z′, 0.66; S/B ratio,
5.8; and one hit. The only positive hit is the polynegatively charged
suramin (Figure S6b).
Conclusions
In this article, we discovered that T5 exonuclease completely degraded
(−) sc plasmid pAB1 that carries an AT hairpin structure. In
contrast, T5 exonuclease did not digest rx plasmid pAB1. Using this
unique property of T5 exonuclease, we developed a series of HTS assays
that could be used to identify inhibitors targeting various DNA topoisomerases.
We also developed an HTS assay to identify inhibitors for T5 exonucleases
and potential DNA intercalators. We validated these HTS assays using
a 50-compound library. All HTS assays have a Z′ more than 0.5
and are ready to screen different compound libraries. Additionally,
we found that compound NSC668394, an ezrin inhibitor potently inhibit
both EcTopI and HuTopI. It is likely that NSC668394 inhibits EcTopI
and HuTopI through the formation of covalent bonds with the thiol
groups of cysteine residues of these two enzymes. An advantage of
these fluorescence-based HTS assays is that they are cost-friendly
and accessible to many labs. The T5 exonuclease-based assay can also
be used to identify DNA intercalators, the major false positives for
DNA topoisomerase inhibitor campaigns. Additionally, these HTS assays
may be used as the orthogonal screening assays for other HTS assays,
such as SDFQ-based HTS assays to identify topoisomerase inhibitors.[33]
Experimental Section
Proteins, DNA Samples,
and Other Materials
E. coli DNA topoisomerase I was purified according
to our previously published procedure.[37]E. coliDNA gyrase subunit A and
subunit B were purified as previously described.[34]Variola DNA topoisomerase I was purified
as previously described.[34] A His-tagged
T5 exonuclease was purified from E. coli strain BLR(DE3) carrying plasmid pET28a(+)-His-T5E using a Ni-NTA
column followed by a Q Sepharose Fast Flow column. The His-tag may
be removed by TEV protease.Plasmid pAB1, a derivative of pUC18,
was constructed as described previously.[33] (−) sc plasmids pAB1 and pUC18 were purified from E. coli cells harboring the plasmids (Top10/pAB1
or Top10/pUC18). Rx plasmid pAB1 was relaxed using variola DNA topoisomerase I or E. coli DNA
topoisomerase I and purified with phenol extraction and ethanol precipitation.A double fluorophore-labeled oligomer HP1 5′-[FI]-CGCTGTCGAACACACGCTTGCGTGTGTTC-[TAMRA]-3′
was purchased from Eurofins Genomics LLC and used without further
purification. An extinction coefficient of 301,301 M–1 cm–1 was used to determine the concentration of
HP1.Novobiocin, ciprofloxacin, ethidium bromide, and Hoechst
33258
were purchased from Sigma-Aldrich, Inc. SYBR gold, SYBR green, and
ethidium homodimer 1 (EthD1) were bought from ThermoFisher Scientific,
Inc. NSC compounds were obtained from NCI DTP program (https://dtp.cancer.gov).
DNA Supercoiling Assays
DNA supercoiling
assays by E. coliDNA gyrase were carried
out in 30 μL
of 1× DNA gyrase buffer (20 mM Tris-acetate pH 7.9, 50 mM KAc,
10 mM MgCl2, 2 mM DTT, 1 mM ATP, 0.1 mg/mL BSA) using 20
nM E. coliDNA gyrase and 200 ng of
the rx pAB1. The reactions were incubated at 37 °C for 15 min
and then stopped with the addition of EDTA to 10 mM and SDS to 1%.
The topological state of DNA samples was analyzed by 1% agarose gel
electrophoresis in 1× TAE buffer followed by ethidium bromide
staining and photographing.
T5 Exonuclease-Based Assays to Identify Inhibitors
for E. coli DNA Gyrase
All
assays were conducted
in 384-well plates using 30 μL of 1× gyrase buffer. In
a typical assay, 20 nM E. coli DNA
gyrase was used to supercoil rx pAB1 (200 ng; 10 μM (bp)) at
37 °C for 30 min. The E. coligyrase
was incubated with a gyrase inhibitor or a chemical compound at 37
°C for 5 min before the rx pAB1 was added into the reaction mixtures.
Next, 200 nM T5 exonuclease was added into the reaction mixtures.
The 384-well plate was incubated at 37 °C for additional 120
min. After ethidium homodimer 1 (EthD1) or another DNA-binding dye
was added to each well, the fluorescence was measured in a microplate
reader. For EthD1, fluorescence was measured at λem of 617 nm with λex = 528 nm.The Z-factor (Z′) was determined using
the 96 wells of a 384-well plate where 48 wells are for positive controls
in the presence of 3 μM novobiocin and the remaining 48 wells
for negative controls in the absence of novobiocin. Z′ was calculated by the following equation:where σp, σn, μp, and μn represent the sample
means and standard deviations for positive (p) and negative (n) controls,
respectively.
T5 Exonuclease-Based Assays to Identify Inhibitors
for E. coli and Variola DNA Topoisomerase
I
All assays were conducted in 384-well plates using 1×
CutSmart buffer (20 mM Tris-acetate pH 7.9, 50 mM KAc, 10 mM Mg(AC)2, and 100 μg/mL BSA). Briefly, 20 nM E. coli or variola DNA topoisomerase
I (nM) was used to relax the (−) sc pAB1 (200 ng; 10 μM
(bp)) at 37 °C for 30 min in the presence of a potential inhibitor.
The E. coli or variola DNA topoisomerase I was incubated with a potential inhibitor at
37 °C for 5 min before the sc pAB1 was added into the reaction
mixtures. Next, 200 nM T5 exonuclease was added into the reaction
mixtures. The 384-well plate was incubated at 37 °C for additional
120 min. After ethidium homodimer 1 (EthD1) was added to each well,
the fluorescence was measured in a microplate reader.
T5 Exonuclease-Based
Assays to Identify DNA Intercalators
These assays are identical
to the T5 exonuclease-based assays for E. coli and variola DNA topoisomerase
I except E. coli, and variola DNA topoisomerase I are omitted. Briefly, 30 μL of 1×
CutSmart buffer containing 200 ng of (−) sc pAB1 in the presence
of a potential DNA intercalator is used. Next, 200 nM T5 exonuclease
was added into the reaction mixture. The 384-well plate was incubated
at 37 °C for additional 120 min. After ethidium homodimer 1 (EthD1)
was added to each well, the fluorescence was measured in a microplate
reader.
Authors: Siddhartha Roychoudhury; Kelly M Makin; Tracy L Twinem; David T Stanton; Sandra L Nelson; Carl E Catrenich Journal: J Biomol Screen Date: 2003-04
Authors: Eddy E Alfonso; Zifang Deng; Daniel Boaretto; Becky L Hood; Stefan Vasile; Layton H Smith; Jeremy W Chambers; Prem Chapagain; Fenfei Leng Journal: ACS Pharmacol Transl Sci Date: 2022-09-02